VG Life Sciences Competitors and Similar CompaniesClear all
Epizyme's competitors and similar companies include Syndax Pharmaceuticals and Oncolytics Biotech.
 Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors. |  Syndax Pharmaceuticals Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy. |  Oncolytics Biotech Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies. | |
Founding Date | Founding Date 2007 | Founding Date 2005 | Founding Date 1998 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Cambridge, US HQ | Locations Waltham, US HQ New York, US Waltham, US | Locations Calgary, CA HQ Calgary, CA San Diego, US |
Employees | Employees 20364% increase | Employees 358% decrease | Employees 28 |
Valuation ($) | Valuation ($) 250.8 m | Valuation ($) 1.6 b | Valuation ($) 93.9 m |
Financial | |||
Revenue (est.) | Revenue (est.) $37.4m (FY, 2021) | Revenue (est.) $172.4m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods $10.5m (FY, 2021) | Cost of goods N/A | Cost of goods N/A |
Net income | Net income ($251.1m) (FY, 2021) | Net income ($285.4m) (FY, 2025) | Net income ($28.8m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 51.5m | Total funding raised N/A | Total funding raised $ 24m |
For sources of this data, please see the company profile
View Company Profiles
Syndax Pharmaceuticals
HQ
Waltham, US
Employees
35↓ 8% decrease
Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.
View companyOncolytics Biotech
HQ
Calgary, CA
Employees
28
Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies.
View company